Bicara Therapeutics
A clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. . Learn more
Launch date
Employees
Market cap
$1.4b
Enterprise valuation
$1.2b (Public information from Sep 2024)
Share price
$25.61 BCAX
Cambridge Massachusetts (HQ)
Authorizing premium user...